| Authors | Kimmel, L.A. Liew, S.M. Sayer, J.M. Holland, A.E. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Medical Journal of Australia |
| Year of Publication | 2016 |
| URL | https://www.mja.com.au/journal/2016/205/2/hip4hips-high-intensity-physiotherapy-hip-fractures-acute-hospital-setting |
| DOI | /10.5694/mja16.00091 |
| Download |  105694mja16_00091_.pdf (256.0 KB) |
| Abstract | Objectives: To investigate the effects of intensive acute hospital physiotherapy for patients with isolated hip fractures. Design, setting: Single-institution, prospective, randomised trial at a level 1 trauma centre in Melbourne, March 2014 - January 2015. Participants: 92 patients aged 65 years or more with isolated hip fractures. Patients were excluded if the fracture was subtrochanteric or pathological, or if post-operative orders required the patient to be non-weight-bearing on the operated leg. Interventions: Randomisation to usual care physiotherapy (daily; control group) or intensive physiotherapy (three times daily; intervention group). Main outcome measures: Outcomes were assessed at post-operative Day 5, at discharge, and at 6 months. The primary outcome was the modified Iowa Level of Assistance (mILOA) score, with other outcome measures including Timed Up and Go test performance and hospital length of stay (LOS). Results: After controlling for sex, anaesthetic type and home setting, the between-group difference in Day 5 mILOA score favoured the intervention group (mean difference v control group, -2.7 points; P = 0.04). Hospital LOS was also shorter for the intervention group (median, 24.4 days v 35.0 days; P = 0.01). A Cox proportional hazard model that controlled for potential confounders indicated that the probability of discharge was greater for intervention group patients at all time points following surgery (P < 0.001). Re-admission and complication rates and 6-month outcomes for the two groups were not significantly different. Conclusions: Intensive acute hospital physiotherapy is safe and reduces hospital LOS after an isolated hip fracture. This has the potential to improve bed flow, given the large numbers of inpatient beds occupied by this patient population. Trial registration: Clinical Trials Registry #NCT02088437 |
http://www.ibas.org.au/what-we-do/publications/3872831
RESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE
The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
ResearchFest 2026 at Austin Health launched new research flagships and honored Professor Mark Howard (Distinguished Scientist) and Professor Eliza Hawkes (Women in Research Award), with insights from Peter Doherty.
We are announcing exciting updates to our Early and Mid-Career Researcher (EMCR) representation at the Institute for Breathing and Sleep (IBAS). The MSRC extend a warm thank you to Charissa Zaga and welcome Jessica Manousakis!
ANZSRS LIFE MEMBERSHIP FOR DANNY BRAZZALE
Danny Brazzale has earned a prestigious ANZSRS Life Membership—held by only 11 people—for his global leadership and dedicated mentorship in respiratory science.
PERTH HIGHLIGHTS: TSANZSRS 2026
A huge congratulations to all our team members who participated in the excellent workshops and meetings at the TSANZSRS Annual Scientific Meeting in Perth in March 2026! Well Done!
© 2026 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
